Phio Pharmaceuticals Corp(PHIO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.34 | Insider Own | 15.07% | Shs Outstand | 11.6M | Perf Week | 0.89% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 57.79% | Insider Trans | 3.89% | Shs Float | 9.9M | Perf Month | -14% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | -0.36 | Inst Own | 5.57% | Short Float | 1.38% | Perf Quarter | -16.5% |
| Income | -0.01B | P/S | - | EPS this Y | 0.34% | Inst Trans | -0.24% | Short Ratio | 1.07 | Perf Half Y | -24.56% |
| Sales | 0.00B | P/B | 0.79 | EPS next 5Y | - | ROA | -100.78% | Short Interest | 0.14M | Perf YTD | -18.1% |
| Book/sh | 1.08 | P/C | 0.77 | EPS past 3/5Y | 74.81% 62.91% | ROE | -113.71% | 52W High | -79.47% ($4.19) | Perf Year | -58.25% |
| Cash/sh | 1.12 | P/FCF | - | Sales past 3/5Y | - | ROIC | -102.4% | 52W Low | 5.82% ($0.81) | Perf 3Y | -92.48% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 59.81% | Gross Margin | - | Volatility(W/M) | 6.17% 6.16% | Perf 5Y | -99.53% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.05 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 8.39 | EPS Q/Q | 21.14% | Profit Margin | - | RSI (14) | 37.05 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 8.39 | Sales Q/Q | - | SMA20 | -6.02% ($0.92) | Beta | 0.92 | Target Price | $14 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/7 | SMA50 | -14.2% ($1) | Rel Volume | 0.52 | Prev Close | $0.86 |
| Employees | 6 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -20.95% ($1.09) | Avg Volume(3M) | 0.13M | Price | $0.86 |
| IPO | 2012/5/10 | Option/Short | No/Yes | Trades | 171 | Volume | 66,663 | Change | -0.3% |
🧬 This is a U.S. clinical-stage biotech developing immuno-oncology drugs using its proprietary siRNA-based gene silencing technology called "INTASYL." Its lead pipeline candidate, PH-762, is an injectable that directly silences the PD-1 gene, and it has produced positive early-stage clinical results in patients with skin cancer who are not candidates for surgery. The company is a tiny, Nasdaq-listed firm.
Over the past 1 year, on the lower side
79% below its 1-year high.
Traded less than usual. That is 52% of its average volume.
PHIO has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +0.3% this year.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -99.5%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 5.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #504 of 597 in the industry
Based on market cap of $10M.
AZR#503 Azora Therapeutics Inc $10M PER - PHIO#504 Phio Pharmaceuticals Corp $10M PER - 
CALC#505 CalciMedica Inc $10M PER - 
BLRX#506 Bioline Rx Ltd ADR $10M PER - 
TPST#506 Tempest Therapeutics Inc $10M PER - 
FAQ
What kind of company is PHIO?
PHIO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PHIO?
The market cap of PHIO is approximately $10M, ranking 5,432 within its sector.
What is the 52-week high and low for PHIO?
PHIO has recorded a 52-week high of $4.19 and a low of $0.81.
